IDEXX Laboratories Inc (IDXX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
IDEXX Laboratories Inc stock (IDXX) is currently trading at $575.72. IDEXX Laboratories Inc PE ratio is 43.66. IDEXX Laboratories Inc PS ratio (Price-to-Sales) is 10.58. Analyst consensus price target for IDXX is $750.23. WallStSmart rates IDXX as Hold.
- IDXX PE ratio analysis and historical PE chart
- IDXX PS ratio (Price-to-Sales) history and trend
- IDXX intrinsic value — DCF, Graham Number, EPV models
- IDXX stock price prediction 2025 2026 2027 2028 2029 2030
- IDXX fair value vs current price
- IDXX insider transactions and insider buying
- Is IDXX undervalued or overvalued?
- IDEXX Laboratories Inc financial analysis — revenue, earnings, cash flow
- IDXX Piotroski F-Score and Altman Z-Score
- IDXX analyst price target and Smart Rating
IDEXX Laboratories Inc
📊 No data available
Try selecting a different time range
IDXX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · IDEXX Laboratories Inc (IDXX)
IDXX trades 40% above its Graham fair value of $462.85, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
IDEXX Laboratories Inc (IDXX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around peg ratio and price/sales. Fundamentals are solid but monitor weak areas for improvement.
IDEXX Laboratories Inc (IDXX) Key Strengths (5)
Every $100 of shareholder equity generates $66 in profit
Keeps $25 of every $100 in revenue as net profit
95.82% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $30 kept per $100 revenue
Supporting Valuation Data
IDEXX Laboratories Inc (IDXX) Areas to Watch (5)
Very expensive relative to growth, significant premium
Very expensive at 10.6x annual revenue
Very expensive at 28.3x book value
Solid revenue growth at 14.30% per year
Solid earnings growth at 17.90%
Supporting Valuation Data
IDEXX Laboratories Inc (IDXX) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 3.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Profit Margin, Institutional Own.. Profitability is solid with Return on Equity at 66.20%, Operating Margin at 29.80%, Profit Margin at 24.60%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (3.97), Price/Sales (10.58), Price/Book (28.28) suggest expensive pricing. Growth concerns include Revenue Growth at 14.30%, EPS Growth at 17.90%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 66.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 14.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Profit Margin) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IDXX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IDXX's Price-to-Sales ratio of 10.58x trades at a 27% premium to its historical average of 8.33x (85th percentile). The current valuation is 40% below its historical high of 17.67x set in Oct 2007, and 204% above its historical low of 3.48x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for IDEXX Laboratories Inc (IDXX) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
IDEXX Laboratories Inc is a mature, profitable business with steady cash generation. Revenue reached 4.3B with 14% growth year-over-year. Profit margins are strong at 24.6%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 6620.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 24.6% and operating margin of 29.8% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Volatility is elevated with a beta of 1.70, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact IDEXX Laboratories Inc.
Bottom Line
IDEXX Laboratories Inc is a well-established business delivering consistent profitability with 24.6% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About IDEXX Laboratories Inc(IDXX)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.